Screening tools for detection of cognitive impairment.
Abstract
Grow in aging has led to an increasing number of people presenting with cognitive impairment and dementia. Most forms of dementia are classified by means of morphological techniques, assays of biomarkers in cerebrospinal fluid and neuropsychological assessment, into degenerative forms, dementia of vascular type and dementia secondary to other conditions. It is very difficult to make a clear-cut diagnosis of the different types of dementia by means of clinical methods. However, many psychometric tests play a prominent role in screening and evaluation of patients with cognitive impairment. Some tools can help clinicians in differential diagnosis among the various forms of dementia such as the ones that assess clinical aspects, tests that focus on specific cognitive areas or behavioral inventories. Still nowadays, there is not a consensus about the best strategies for screening and assessment of cognitive impairment among elderly subjects. The purpose of this chapter is to make a review of the screening tools and psychometric test instruments that healthcare professionals can use for screening and neuropsychological assessment of geriatric individuals with cognitive disorders to help diagnosis of dementia and to make differential diagnosis of the most common forms of dementia.
Keywords
- psychometric
- cognitive impairment
- dementia
- Alzheimer disease
- vascular dementia
- neuropsychological assessment
- neuropsychology
- mild cognitive impairment
1. Introduction
All countries of the world have observed a substantial increase in the number of elderly people. This phenomenon resulted to an increase of chronic health conditions and cognitive impairments. With the consequence of world population senescence, the healthcare professionals need to differentiate expected changes due to aging from pathological conditions due to dementia.
The current state of knowledge allows a detection of neurodegenerative brain changes [1] with neuroimaging techniques such as magnetic resonance imaging [2] or positron emission tomography with amyloid binding tracers [3] and assays of biomarkers such as beta amyloid fragment or phosphorylated tau protein in cerebrospinal fluid [4]. These techniques make possible to identify degenerative forms of dementia (Alzheimer’s disease, Lewy bodies dementia and frontotemporal dementia), dementia of vascular type and dementia secondary to other conditions (such as traumatic brain injuries, human immunodeficiency infection, substance-induced dementia, Huntington disease, Parkinson’s disease and prion disease).
However, research studies show that preclinical diagnosis of neurodegenerative conditions is still possible with neuropsychological measurement of cognitive changes [5]. Different cognitive tasks used in combination can provide screening and assessment of cognitive impairment among elderly people, since if used together they can bring more information. Psychometric tests are also useful to differentiate pseudo-dementias [6] or other form of primary dementias that may mimic dementia of Alzheimer type such as frontotemporal dementia and Jacob–Creutzfeldt disease, predict increased or reduced risk of dementia and describe disease evolution in affected individuals.
There is no consensus regarding the best strategies for screening of cognitive impairment among elderly patients even if several brief instruments are recommended [7].
Most individuals and their caregivers would want to know a diagnosis of dementia as soon as possible to allow them to make decisions regarding future plans when they are still able to do it [8]. Furthermore, studies conducted to prevent cognitive decline and disability have demonstrated that pharmacological treatments and early interventions on healthy life-style factors such as social interactions, leisure activities, cognitive stimulation, Mediterranean diet and regular physical activity should be encouraged in patients with mid cognitive impairments as possible protectors against neurodegenerative disease of aging and progression of cognitive deficits [9].
2. Screening batteries for detection of cognitive impairment
Clinicians have developed many neuropsychological instruments that are best suited for middle-aged and older people. Brief screening tools are useful for identifying individuals with cognitive disorders, staging their severity, tracking progression over time and response to treatments. Most of them have a general applicability. The sensitivity of the screening test is defined as the number of positives correctively identified by the test as a percentage of the total number of the positives in the population studied (percentage of demented subjects). Conversely the specificity of the screening test is the number of negatives correctly identified by the test as a percentage of all the true negatives (percentage of not demented subjects). Screening tests are summarized in Table 1.
Battery | Total score | Sensitivity % | Specificity % | Cut-off scores | Administration time | Components of the battery |
---|---|---|---|---|---|---|
CDT | 10 | 67–97.9 | 69–94.2 | <7 | 4-5 min | A, VS, E, PR |
Dem-Tect | 18 | 100 | 92 | ≤12 | 8–10 min | M, L, E |
MIS | 8 | 43–86 | 93–97 | ≤4 | 4 min | M |
Mini-Cog | 5 | 76–99 | 85.3–96 | ≤3 | 2 min | A, M, L. VS, E |
MSQ | 10 | 92.3–100 | 86.5–100 | ≥3 | 2 min | O |
SPMSQ | 10 | 92.3–100 | 86.5–100 | ≥3 | 2 min | O, A, MT |
BDRS | 28 | 43 | 94 | ≥4 | 4–5 min | ADL |
VFT | NA | 37–89.5 | 43–97 | 12/13 or 14/15 | 4–5 min | M, L, E |
SLUMS | 30 | 92–100 | 76–100 | 23.5 or 25.5 | 7 min | O, M, L, A, C, VS, E |
RAVLT-IR | 75 | 97.9 | 17.9 | ≤30 | 10–15 min | A, M, L |
RAVLT-DR | 15 | 95.7 | 28.6 | ≤3 | 30 min | M, L |
RAVLT-RT | 15 | 91.5 | 46.4 | <10 | 30–60 min | M, L |
RAVLT-FC | 15 | 92.6 | 67.9 | <13 | 30–60 min | M, L |
ACE-R | 100 | 84–94 | 89–100 | 82 or 88 | 20 min | O, M, L, A, VS, E |
CAMCOG | 106 | 92 | 96 | <80 | 30 min | O, L, M, A, PR, CA, AT, PE, VS |
MMSE | 30 | 88.3 | 86.2 | 23/24 or 24/25 | 6–10 min | O, M, L, A, C, VS, PR |
MoCA | 30 | 90–100 | 87 | 26 | 6–10 min | O, M, L, A, E, C, VS, PR |
Some researchers consider the
The CDT has 67 to 97.9% sensitivity and 69 to 94.2% specificity in screening cognitive impairment [13]. It cannot be used among people with visual or motor difficulties that prevent them from using properly paper and pen. There is not a consensus on whether the CDT can distinguish mild cognitive impairment (MCI) from dementia even if this test can assess motor and executive functions, memory and verbal comprehension and has been used to differentiate dementia from cognition in different studies [14]. Finally, there are also multiple scoring methods for interpreting CDT (with different degree of complexity), and there is no consensus on the best method [13].
The
The
The
The
The
The
The
The
The
Many clinicians and researchers also include a recognitions trial (RAVLT-RT) that is assessed after a time of 30–60 minutes first developed by Lezak [32]. In the recognition task, the examiner asks the patient to identify as many words as possible from the first list when shown a list of 50 words containing words that are semantically associated or phonemically similar of the 15-words target list.
Porech et al. presented in 2016 an auditory verbal learning forced-choice recognition task (RAVLT-FC) and proposed its use as part of a routine neuropsychological assessment [33]. In this procedure, the examiner reads a pair of words and asks the subject to choose the word from each pair that had been presented in the original list. The RAVLT-FC is then composed of 15 FC items, each consisting of the target list of 15 words paired with 15 distractors. RAVLT-FC total score consists in the number of words correctly identified; maximum score is 15. Authors have considered for each trial cut off scores that minimize risk of false positive and that have high specificity values. According to a recent study on the validity of the Rey auditory verbal learning test, RAVL-IR (total 1–5 trial) at a level of cut-off less than 30 has a specificity of 97.9% and sensitivity of 17.9%; RAVL-DR (long delay recall) at a level of cut-off less than 3 has a specificity of 95.7% and sensitivity of 28.6%; RAVL-RT (recognition task) at a level of cut-off less than 10 has a specificity of 91.5% and sensitivity of 46.4%; RAVL-FC (forced-choice trial total score) at a level of cut-off less than 13 has a strong specificity (92.6%) and a sensitivity of 67.9% [34]. As in all learning tests, age effects are prominent and tend to affect all the relevant measures [35].
The
The
However, MMSE is not suitable for the screening of the initial phases of dementia and is not useful to evaluate executive functions. It is effective in discriminating patients with moderate or greater cognitive deficits from control subjects [45]. It is sensitive for the follow up of progressive deterioration in dementing patients [46]. Item analyses indicate that the three-word recall is the most sensible item to dementia while the second most failures are orientation for date [47]. Given to its susceptibility to ceiling effect [48] and sociodemographic factors [49], the MMSE should not be used in isolation to definitively diagnose or rule out of dementia [50].
The
3. Functional assessment of subjects with cognitive deficits
As suggested by Jiang et al. [59], changes in instrumental activities daily living for domestic works are common in patients with mild cognitive impairment. Therefore, it is recommendable the use of functional scales during the screening of subjects with cognitive deficits (Table 2).
Functional scale | Total score | Sensitivity % | Specificity% | Cut-off | Administration time | Cognitive and functional domains of daily living |
---|---|---|---|---|---|---|
IQCODE | 26–130 | 75–83 | 65–90 | 3.3 | 10–20 min | M, O, J, PS, CA, HH, PC |
PFAQ | 30 | 88.3 | 76.5 | >10 | 15–20 min | M, O, J, PS, CA, HH, PC |
CDR | 18 | 95 | 94 | >6 | 20–30 min | M, O, J, PS, CA, HH, PC |
The
The
The
In a study where CDR was used for screening of dementia, the authors found a sensitivity of 95% and a specificity of 94% [64].
The CDR is used in clinical practice and research studies to stage dementia severity and monitor disease progression over times. Since its first version, researchers have developed a modified version of CDR that includes domains of language, behavior and personality disorders to capture a range of symptoms beyond memory impairment associated with less common dementia types [65].
4. Assessment of cognitive functions in demented patients
Comprehensive test batteries provide a baseline of an individual with dementia and monitor symptoms progression over time. Most of the psychometric test planned for the examination of dementia consist in batteries that incorporates pre-existing neuropsychological tests that their creators brought together [66]. Each battery generally contains published tests or tasks specifically developed for the battery. The neuropsychological evaluation typically includes a clinical interview and assessment of different cognitive domains [67].
The entire neuropsychological exam can take from several minutes to several hours on the bases of the battery of tests used. The most common batteries used in assessment of cognitive functions are summarized in Table 3.
Battery | Sub-tests | Administration time | Main cognitive functions explored |
---|---|---|---|
IBMD | TO; BVRT; COWAT | 10–20 minutes | O, VS, L, M, E, PR, VS |
DAB | FTT; FDS; NT; ViMT; VeMT; TT; WFT; SDST; CD; NCT | 45 min | A, L, M, E, AT, VS |
CERAD | VFT; NT; MMSE; WLMT; CP; WLRecall; WLRecog | 20–30 min | O, L, E, M, A, VS, PR, C |
MFI | MMSE; RCPM; SDST | 15–25 min | O, M, L, A, VS, AT |
NSB | GENERAL NEUROPSYCHOLOGY TESTS | 30–45 min | O, A, M, L, VS, PR |
MDB | VFT; PC; WLMT; RCPM; ViMT; CD | 40–75 min | VS, L, M, AT, VS, PR |
CCT | PinfT; CAT; PIntT; MT; PRS; MF; VR; RLDO | 45 min | O, AT, VS, M |
DRS | FDS; FTT; CD; VeMT | 30–45 min | A, E, PR, AT, M |
ABCD | MSQ; SR; WLMT; NT; VC; CD | 45–90 min | O, L, M, PR |
CSD | VT; VR; VSR; VeMT; OM | 120 min | L, E, VS, M |
ADAS | MSQ; BSQ | 45 min | O, L, M, PR |
5. Neuropsychological batteries
The
Another battery of tests generally used for assessment of dementia is the
Probably the best known of dementia batteries is that developed by the
The
The
The
Some psychometric test has been specifically designed to measure competency of elderly patients with dementia [66].
The
The
The
Some
The
6. Psychometric tools for differential diagnosis of cognitive impairment
Psychometric assessment with specific tools can help clinicians in the process of differential diagnosis of cognitive impairments and dementia (see Table 4).
Type of Cognitive impairment | Psychometric tools for differential diagnosis |
---|---|
Mild cognitive impairment | MMSE, MoCA, ACE-R, DemTect, IQCODE, CAMCOG, SLUMS |
Alzheimer’s disease | MMSE, MoCA, MIS, Mini-Cog, CDT, RAVLT, CAMCOG, NPI, Behave-AD |
Frontotemporal dementia | FAB, Exit-25 |
Vascular cognitive impairment | HIS, TMT, DS, MMSE, CAMCOG, ACE-R, MoCA |
Parkinson’s disease dementia | MoCA, SCOPA-COG, ACE-R, PD-CRS |
Alzheimer’s disease (AD) is the most common form of degenerative dementia. The typical presentation consists in memory impairment and executive dysfunction interfering with daily life activities [92]. Many tests have been validated for screening of patients with moderate Alzheimer’s disease such as
Some psychometric tools such as
Cerebrovascular diseases are a common cause of cognitive impairments known as
7. Conclusions
There are many neuropsychological tools for screening and assessment of cognitive functions among elderly people. Scales, inventories and other tests designed for the screening of dementia contain items and tasks that are sensitive to the most common dementing processes especially recent and remote memory and some aspects of attention. The
For a detailed cognitive profile of the dementia and differential diagnosis of the different forms of dementia, examiners must explore many cognitive areas that include memory, attention, executive functions, language and visuo-spatial functions. It involves the use of neuropsychological batteries of tests, each one measuring a distinct cognitive ability with greater sensitivity and specificity than a screening toll. Diagnostic accuracy may be enhanced by combining data from several of the instruments described in this chapter.
Neuropsychological measurements play an important role in identification conditions of normal aging, dementia assessment, prediction of development of cognitive impairment, measurement of residual functional abilities and identification of possible targets of intervention [109].
However, still nowadays it is necessary to create new cognitive instruments used by general practitioners within primary care services as routine procedures in order to reduce negative effects of dementia on elderly people.
References
- 1.
Tomlinson BE. The structural and quantitative aspects of the dementias. In: Roberts PJ, editor. Biochemistry of Dementia. Chichester: Wiley; 1980. pp. 15-52 - 2.
Schoonenboom NS, van der Flier WM, Blankenstein MA, et al. CSF and MRI markers independently contribute to the diagnosis of Alzheimer’s disease. Neurobiology of Aging. 2008; 29 :669-675 - 3.
Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer’s disease with Pittsburgh compound-B. Annals of Neurology. 2004; 55 :306-319 - 4.
Shaw LM, Vanderstichele H, Knapik-Czajka M, et al. Cerebrospinal fluid biomarker signature in Alzheimer’s disease neuroimaging initiative subjects. Annals of Neurology. 2009; 65 :403-413 - 5.
Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s Dement. 2011; 7 :280-292 - 6.
Wells CE. Pseudodementia. Am. J. Psychiat. 1979; 136 :895-900 - 7.
Yassuda MS, da Silva HS, Lima-Silva TB, et al. Normative data for the brief cognitive screening battery stratified by age and education. Dement Neuropsychol. 2017; 11 (1):48-53 - 8.
Prorok JC, Horgan S, Seitz DP. Health care experiences of people with dementia and their caregivers: A meta-ethnographic analysis of qualitative studies. CMAJ. 2013; 185 (14):E669-E680 - 9.
Kivipelto M, Solomon A, Ahtiluoto S, et al. The Finnish geriatric intervention study to prevent cognitive impairment and disability (FINGER): Study design and progress. Alzheimer’s Dement. 2013; 9 (6):657-665 - 10.
Reiner K, Eichler T, Hertel J, Hoffmann W, Thyrian JR. The clock drawing test: A reasonable instrument to assess probable dementia in primary care? Current Alzheimer Research. 2018; 15 (1):38-43 - 11.
Sunderland T, Hill JL, Mellow AM, et al. Clock drawing in Alzheimer’s disease. Journal of the American Geriatrics Society. 1989; 37 (8):725-729 - 12.
Shulman KI, Shedletsky R, Silver IL. The challenge of time: Clock-drawing and cognitive function in the elderly. International Journal of Geriatric Psychiatry. 1986; 1 (2):135-140 - 13.
Lin JS, O’Connor E, Rossom RC, et al. Screening for cognitive impairment in older adults: A systematic review for the U.S. preventive services task force. Annals of Internal Medicine. 2013; 159 (9):601-612 - 14.
Lourenço RA, Ribeiro-Filho ST, Moreira Ide F, Paradela EM, Miranda AS. The clock drawing test: Performance among elderly with low educational level. Braz J Psychiatry. 2008; 30 (4):309-315 - 15.
Kalbe E, Kessler J, Calabrese P, et al. DemTect: A new, sensitive cognitive screening test to support the diagnosis of mild cognitive impairment and early dementia. International Journal of Geriatric Psychiatry. 2004; 19 (2):136-143 - 16.
Buschke H, Kuslansky G, Katz M, et al. Screening for dementia with the memory impairment screen. Neurology. 1999; 52 (2):231-238 - 17.
Cordell CB, Borson S, Boustani M, et al. Alzheimer’s association recommendations for operationalizing the detection of cognitive impairment during the Medicare annual wellness visit in a primary care setting. Alzheimer’s Dement. 2013; 9 (2):141-150 - 18.
Borson S, Scanlan JM, Chen P, Ganguli M. The mini-cog as a screen for dementia: Validation in a population-based sample. Journal of the American Geriatrics Society. 2003; 51 (10):1451-1454 - 19.
Borson S, Scanlan J, Brush M, et al. The mini-cog: A cognitive ‘vital signs’ measure for dementia screening in multi-lingual elderly. International Journal of Geriatric Psychiatry. 2000; 15 (11):1021-1027 - 20.
Fowler NR, Perkins AJ, Gao S, Sachs GA, Boustani MA. Risks and benefits of screening for dementia in primary care: The Indiana University cognitive health outcomes investigation of the comparative effectiveness of dementia screening (IU CHOICE) trial. Journal of the American Geriatrics Society. 2020; 68 (3):535-543 - 21.
Kahn RL, Miller NE. Assessment of altered brain function in the aged. In: Storandt M, Siegler I, Ellis M, editors. The Clinical Psychology of Aging. New York: Plenum Press; 1978 - 22.
de Leon MJ, George AE, Ferris SH. Computed tomography and positron emission tomography correlates of cognitive decline in aging and senile dementia. In: Poon LW, editor. Handbook for Clinical Memory Assessment of Older Adults. Washington, DC: American Psychological association; 1986 - 23.
Kasniak AW. The neuropsychology of dementia. In: Grant I, Adams KM (Eds). Neuropsychological Assessment of Neuropsychiatric Disorders. New York: Oxford University Press. 1986 - 24.
Fillebaum GG. Comparison of two brief tests of organic brain impairment, the MSQ and the short portable MSQ. Journal of the American Geriatrics Society. 1980; 28 :381-384 - 25.
Pfeiffer E. SPMSQ: Short Portable Mental Status Questionnaire. Journal of the American Geriatric Society. 1975; 23 :433-441 - 26.
Blessed G, Tomlison BE, Roth M. The association between quantitative measures of dementia and of senile changes in the cerebral grey matter of elderly subjects. British Journal of Psychiatry. 1968; 114 :797-811 - 27.
Eastwood MR, Lautenschlaegar E, Corbin S. A comparison of clinical methods for assessing dementia. Journal of the American Geriatrics Society. 1983; 31 (6):342-347 - 28.
Mant A, Eyland EA, Pond DC, Saunders A, Chancellor AHB. Recognition of dementia in general practice: Comparison of general practioner’s opinion with assessment using the mini mental state examination and the Blessed dementia rating scale. Family Practice. 1988; 6 (3):184-188 - 29.
Isaacs B, Akhtar AJ. The set test: A rapid test of mental function in old people. Age and Ageing. 1972; 1 (4):222-226 - 30.
Tariq SH, Tumosa N, Chibnall JT, et al. Comparison of the Saint Louis university mental status examination and the mini-mental state examination for detecting dementia and mild neurocognitive disorder—A pilot study. The American Journal of Geriatric Psychiatry. 2006; 14 (11):900-910 - 31.
Rey A. L’examen Clinique en psychologie. Paris: Presses Universitaries de France; 1964 - 32.
Lezak MH. Neuropsychological Assessment. 2nd ed. New York, NY: Oxford University Press; 1983 - 33.
Poreh A, Bezdicek O, Korobkova I, Levin JB, Dines P. The Rey auditory verbal learning test forced-choice recognition task: Base-rate data and norms. Applied Neuropsychology: Adult. 2016; 23 :155-161 - 34.
Ashendorf L, Sugarman MA. Evaluation of performance validity using a Rey auditory verbal learning test forced-choice trial. The Clinical Neuropsychologist. 2016; 30 (4):599-609 - 35.
IvniK RJ, Malec JF, Smith GE, et al. Mayo’s older Americans normative studies: Updated AVLT norms for ages 56-97. The Clinical Neuropsychologist. 1992; 6 :83-104 - 36.
Larner AJ, Mitchell AJ. A meta-analysis of the accuracy of the Addenbrooke’s cognitive examination (ACE) and the Addenbrooke’s cognitive examination-revised (ACE-R) in the detection of dementia. International Psychogeriatrics. 2014; 26 (4):555-563 - 37.
Huppert FA, Brayne C, Gill C, et al. CAMCOG—A concise neuropsychological test to assist dementia diagnosis: Socio-demographic determinants in an elderly population sample. The British Journal of Clinical Psychology. 1995; 34 (4):529-541 - 38.
Roth M, Tym E, Mountjoy C, et al. A standardised instrument for the diagnosis of mental disorder in the elderly with special reference to the early detection of dementia. The British Journal of Psychiatry. 1986; 149 (6):698-709 - 39.
Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research. 1975; 12 (3):189-198 - 40.
Swain DG, O’Brien AG, Nightingale PG. Cognitive assessment in elderly patients admitted to hospital: The relationship between the abbreviated mental test and the mini-mental state examination. Clinical Rehabilitation. 1999; 13 (6):503-508 - 41.
Arevalo-Rodriguez I, Pedraza OL, Rodriguez A, et al. Alzheimer’s disease dementia guidelines for diagnostic testing: A systematic review. Am J Alzheimer’s Dis Other Demen. 2013; 28 :111-119 - 42.
Rait G, Fletcher A, Smeeth L, et al. Prevalence of cognitive impairment: Results from the MRC trial of assessment and management of older people in the community. Age and Ageing. 2005; 34 (3):242-248 - 43.
Cockrell JR, Folstein MF. Mini-mental state examination. In: Abou-Saleh MT, Katona CLE, Anand KA, editors. Principles and Practice of Geriatric Psychiatry. 2002 ed. Chichester, West Sussex, UK: John Wiley & Sons, Ltd.; 2002. pp. 140-141 - 44.
Young J, Meagher D, Maclullich A. Cognitive assessment of older people. BMJ. 2011; 343 :d5042 - 45.
Filley CM, Davis KA, Schmitz SP, et al. Neuropsychological performance and magnetic resonance imaging in Alzheimer’s disease and normal aging. Neuropsychiatry, Neuropsychology and Behavioural Neurology. 1989; 2 :81-91 - 46.
Morris JC, Heyman A, Mohs RC, et al. The consortium to establish a registry for Alzheimer’s disease (CERAD). Part I. clinical and neuropsychological assessment of Alzheimer’s disease. Neurology. 1989; 39 :1159-1165 - 47.
Galasko D, Klauber MR, Hofstetter CR, et al. The mini mental state examination in the early diagnosis of alzheimer’s disease. Archives of Neurology. 1990; 47 :49-52 - 48.
Tombaugh TN, McIntyre NJ. The mini-mental state examination: A comprehensive review. Journal of the American Geriatrics Society. 1992; 40 :922-935 - 49.
Jones RN, Gallo JJ. Education bias in the mini-mental state examination. International Psychogeriatrics. 2001; 13 :299-310 - 50.
Pangman VC, Sloan J, Guse L. An examination of psychometric properties of the mini-mental state examination and the standardized minimental state examination: Implications for clinical practice. Applied Nursing Research. 2000; 13 (4):209-213 - 51.
Nasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal cognitive assessment, MoCA: A brief screening tool for mild cognitive impairment. Journal of the American Geriatrics Society. 2019; 67 (9):1991 - 52.
Trzepacz PT, Hochstetler H, Wang S, et al. Relationship between the Montreal cognitive assessment and mini-mental state examination for assessment of mild cognitive impairment in older adults. B M C Geriatr. 2015; 15 :107 - 53.
Cecato JF, Montiel JM, Bartholomeu D, Martinelli JE. Poder preditivo do MoCa na avaliação neuropsicológica de pacientes com diagnóstico de demência. Rev Bras Geriatr Gerontol. 2015; 17 (4):707-719 - 54.
Nasreddine ZS, Phillips NA, Be’dirian V, et al. The Montreal cognitive assessment, MoCA: A brief screening tool for mild cognitive impairment. Journal of the American Geriatrics Society. 2005; 53 (4):695-699 - 55.
Huntzinger JA, Rosse RB, Schwartz BL, Ross LA, Deutsch SI. Clock drawing in the screening assessment of cognitive impairment in an ambulatory care setting: A preliminary report. General Hospital Psychiatry. 1992; 14 (2):142-144 - 56.
Sobreira E, Pena-Pereira MA, Eckeli AL, et al. Screening of cognitive impairment in patients with Parkinson’s disease: Diagnostic validity of the Brazilian versions of the Montreal cognitive assessment and the Addenbrooke’s cognitive examination-revised. Arquivos de Neuro-Psiquiatria. 2015; 73 (11):929-933 - 57.
Coleman KK, Coleman BL, MacKinley JD, et al. Detection and differentiation of frontotemporal dementia and related disorders from Alzheimer disease using the Montreal cognitive assessment. Alzheimer Disease and Associated Disorders. 2016; 30 :258-263 - 58.
Marras C, Armstrong MJ, Meaney CA, et al. Measuring mild cognitive impairment in patients with Parkinson’s disease. Movement Disorders. 2013; 28 :626-633 - 59.
Jiang C, Xu Y. The association between mild cognitive impairment and doing housework. Aging & Mental Health. 2014; 18 (2):212-216 - 60.
Jorm AF, Broe GA, Creasey H, et al. Further data on the validity of the informant questionnaire on cognitive decline in the elderly (IQCODE). International Journal of Geriatric Psychiatry. 1996; 11 (2):131-139 - 61.
Morales JM, Bermejo F, Romero M, Del-Ser T. Screening of dementia in community-dwelling elderly through informant report. International Journal of Geriatric Psychiatry. 1997; 12 (8):808-816 - 62.
Pfeffer RI, Kurosaki TT, Harrah CH Jr, Chance JM, Filos S. Measurement of functional activities in older adults in the community. Journal of Gerontology. 1982; 37 (3):323-329 - 63.
Morris JC. The clinical dementia rating (CDR): Current version and scoring rules. Neurology. 1993; 43 (11):2412-2414 - 64.
Juva K, Sulkava R, Erkinjutti T, Ylikiski R, Valvanne J, Tilvis R. Usefulness of the clinical dementia rating scale in screening for dementia. International psychogetiatrics. 1995; 7 :17-24 - 65.
Knopman DS, Weintraub S, Pankratz VS. Language and behavior domains enhance the value of the clinical dementia rating scale. Alzheimer's & Dementia. 2011; 7 :293-299 - 66.
Lezak MH, Howieson BD, Loring DW. The Neuropsychological Examination: Procedures. Neuropsychological Assessment. Fourth ed. New York: Oxford University Press; 2004 - 67.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-V). Arlington (VA): American Psychiatric Association; 2013 - 68.
Stroop JR. Studies of interference in serial verbal reactions. Journal of Experimental Psychology. 1935; 18 (6):643 - 69.
Rey A. L’examen psychologique dans les cas d’ence’phalopathie traumatique. Archives de Psychologie. 1941; 28 :286-340 - 70.
Eslinger PJ, Damasio AR, Benton AL, Van Allen M. Neuropsychologic detection of abnormal mental decline in older persons. Journal of the American Medical Association. 1984; 253 :670-674 - 71.
Teng EL, Wimer C, Roberts E, et al. Alzheimer’s dementia: Performance on parallel forms of the dementia assessment battery. Journal of Clinical and experimental neuropsychology. 1989; 11 :899-912 - 72.
Monsch AU, Bondi MW, Butters N, et al. Comparison of verbal fluency tasks in the detection of dementia of the Alzheimer’s type. Archives of Neurology. 1992; 49 :1253-1258 - 73.
Pfeiffer RI, Kurosaki TT, Chance JM, et al. Use of the mental function index in older adults: Reliability, validity and measurement of change over time. American journal of epidemiology. 1984; 120 :922-935 - 74.
Miceli G, Caltagirone C, Gainotti G. Gangliosides in the treatment of mental deterioration. A doubleblind comparison with placebo. Acta psychiatrica Scandinavica. 1977; 55 :102-110 - 75.
Miceli G, Caltagirone C, Gainotti G, et al. Neuropsychological correlates of localized cerebral lesions in non-aphasic brain-damaged patients. Journal of Clinical Neuropsychology. 1981; 3 :53-63 - 76.
Wang PL, Ennis KE. The Cognitive Competency Test. Toronto: Mt Sinai Hospital, Neuropsychology Laboratory; 1986 - 77.
Mattis S. Dementia Rating Scale (DRS). Odessa, FL: Psychological Assessment Resources; 1988 - 78.
Vitaliano PP, Breen AR, Russo J, et al. The clinical utility of the dementia rating scale for assessing Alzheimer’s patients. Journal of Chronic Disorders. 1984; 37 :743-753 - 79.
Prinz PN, Vitaliano PP, Vitiello MV, et al. Sleep, EEG and mental changes in senile dementia of the Alzheimer’s type. Neurobiology of Aging. 1982; 3 :361-370 - 80.
Janowsky JS, Shimamura AP, Kritchevsky M, Squire LR. Cognitive impairment following frontal damage and its relevance to human amnesia. Behavioural Neuroscience. 1989; 193 :548-560 - 81.
Bayles KA, Tomoeda CK. Arizona Battery for Communication Disorders of Dementia. Gaylord MI: National Rehabilitation Services; 1989 - 82.
Bayles KA, Boone DR, Tomoeda CK, et al. Differentiating Alzheimer’s patients from the normal elderly and stroke patients with aphasia. Journal of Speech and Hearing Disorders. 1989; 54 :74-87 - 83.
Christensen KJ, Multhaup KS, Nordstrom S, Voss K. A cognitive battery for dementia: Development and measurement characteristic. Psychological Assessment. 1991; 3 :168-174 - 84.
Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer’s disease. American Journal of Psychiatry. 1984; 141 :1356-1364 - 85.
Petersen RC, Smith GE, Waring SC, et al. Mild cognitive impairment: Clinical characterization and outcome. Archives of Neurology. 1999; 56 (3):303-308 - 86.
Winblad B, Palmer K, Kivipelto M, et al. Mild cognitive impairment-beyond controversies, towards a consensus: Report of the international working group on mild cognitive impairment. Journal of Internal Medicine. 2004; 256 :240-246 - 87.
Petersen RC, Stevens JC, Ganguli M, et al. Practice parameter: Early detection of dementia: Mild cognitive impairment (an evidence-based review) report of the quality standards Subcommittee of the American Academy of neurology. Neurology. 2001; 56 (9):1133-1142 - 88.
Mitchell AJ. A meta-analysis of the accuracy of the mini-mental state examination in the detection of dementia and mild cognitive impairment. Journal of Psychiatric Research. 2009; 43 (4):411-431 - 89.
Ciesielska N, Sokolowski R, Mazur E, et al. Is the Montreal cognitive assessment (MoCA) test better suited than the mini-mental state examination (MMSE) in mild cognitive impairment (MCI) detection among people aged over 60? Meta-analysis. Psychiatr Pol. 2016; 50 (5):1039-1052 - 90.
Mioshi E, Dawson K, Mitchell J, et al. The Addenbrooke’s cognitive examination revised (ACE-R): A brief cognitive test battery for dementia screening. International Journal of Geriatric Psychiatry. 2006; 21 (11):1078-1085 - 91.
Lonie JA, Tierney KM, Ebmeier KP. Screening for mild cognitive impairment: A systematic review. International Journal of Geriatric Psychiatry. 2009; 24 (9):902-915 - 92.
Scheltens P, Blennow K, Breteler MM, et al. Alzheimer’s disease. Lancet. 2016; 388 (10043):505-517 - 93.
Callahan BL, Ramirez J, Berezuk C, et al. Predicting Alzheimer’s disease development: A comparison of cognitive criteria and associated neuroimaging biomarkers. Alzheimer’s Res Ther. 2015; 7 (1):68 - 94.
Craik FIM. Age differences in human memory. In: Birren JE, Schaie KW, editors. Handbook of the Psychology of Aging. New York: Van Nostrand Reinhold; 1977 - 95.
Bigler ED, Rosa L, Schultz F, et al. Rey auditory verbal learning and Rey-Osterrieth complex figure design performance in Alzheimer’s disease and closed head injury. Journal of Clinical Psychology. 1989; 45 :277-280 - 96.
Saari T, Koivisto A, Hintsa T, et al. Psycometrico properties of the neuropsychiatric inventory: A review. Journal of Alzheimer’s disease. 2022; 86 (4):1485-1499 - 97.
Reisberg B, Borenstein J, Franssen E, et al. Behave-AD: A clinical rating scale for the assessment of pharmacologically remediable behavioral symtomatology in Alzheimer’s disease. In: Altman HJ, editor. Alzhemer’s Disease. New York: Plenum; 1987 - 98.
Bentvelzen A, Aerts L, Seeher K, et al. A comprehensive review of the quality and feasibility of dementia assessment measures: The dementia outcomes measurement suite. Journal of the American Medical Directors Association. 2017; 18 (10):826-837 - 99.
Dubois B, Slachevsky A, Litvan I, et al. The FAB: A frontal assessment battery at bedside. Neurology. 2000; 55 (11):1621-1626 - 100.
Wildgruber D, Kischka U, Faßbender K, et al. The frontal lobe score: Part II: Evaluation of its clinical validity. Clinical Rehabilitation. 2000; 14 (3):272-278 - 101.
Royall DR, Mahurin RK, Gray KF. Bedside assessment of executive cognitive impairment: The executive interview. Journal of the American Geriatrics Society. 1992; 40 (12):1221-1226 - 102.
Hachinski VC, Iliff LD, Zilkha E, et al. Cerebral blood flow in dementia. Archives of Neurology. 1975; 32 :632-637 - 103.
Loeb C. Clinical diagnosis of multi-infarct dementia. In: Amaducci L, Davison AN, Antuono P, editors. Aging of the Brain and Dementia, Aging. Vol. 13. New York: Raven Press; 1980. pp. 251-260 - 104.
O’sullivan M, Morris R, Markus H. Brief cognitive assessment for patients with cerebral small vessel disease. Journal of Neurology, Neurosurgery, and Psychiatry. 2005; 76 (8):1140-1145 - 105.
Lees R, Selvarajah J, Fenton C, et al. Test accuracy of cognitive screening tests for diagnosis of dementia and multidomain cognitive impairment in stroke. Stroke. 2014; 45 (10):3008-3018 - 106.
Dalrymple-Alford J, MacAskill M, Nakas C, et al. The MoCA well-suited screen for cognitive impairment in Parkinson disease. Neurology. 2010; 75 (19):1717-1725 - 107.
Marinus J, Visser M, Verwey N, et al. Assessment of cognition in Parkinson’s disease. Neurology. 2003; 61 (9):1222-1228 - 108.
Pagonabarraga J, Kulisevsky J, Llebaria G, et al. Parkinson’s disease-cognitive rating scale: A new cognitive scale specific for Parkinson’s disease. Movement Disorders. 2008; 23 (7):998-1005 - 109.
Pasternak E, Smith G. Cognitive and neuropsychological examination of the elderly In: DeKosky ST, Asthana S, editors. Handbook of Clinical Neurology, Vol. 167 (3rd series) Geriatric Neurology. University of Florida, Gainesville, FL, USA: Elsevier B.V.; 2019. DOI: 10.1016/B978-0-12-804766-8.00006-6